SoylentNews is people
SoylentNews
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.
(Score: 1, Informative) by Anonymous Coward on Sunday April 15 2018, @09:28AM (1 child)
> The cost of bringing a new drug to market is estimated to be about $2.5bn. This includes development costs and FDA approval for all of the failed attempts until you get the one that works and you can start making money.
Regulation for new drugs has been pushed by the incumbent to stomp out competition and drive prices up, though. If big pharma wanted less regulation, they would get it. Public health? This article proves they can't care less. Just avoid having the pill killing you at once after 30 secs, which is bad PR.
(Score: 2) by qzm on Monday April 16 2018, @01:42AM
And yes, thats EXACTLY what they do, and a cornerstone of the medical system.
Not just that, but the 2.5 Bn figure just happens to INCLUDE the massive overheads and profits of the drug companies as well - so no, it is not even close to a real cost figure.
it is, like most everything in that industry, part of the lie.